Growth Differentiation Factor 11 (GDF-11) is a TGF-β superfamily protein studied in development and age-related animal models. Early mouse papers reported effects in cardiac hypertrophy, brain vascular or neurogenic measures and skeletal muscle, while later work reported increasing GDF11 with age and inhibited muscle regeneration. Those results are not interchangeable: assay specificity, mature-versus-precursor protein, oligomeric state, dose and model all matter. The price list contains six Injectable entries from 0.005 to 1, but it does not state the dosage unit, expression host or protein form.
| Class | TGF-β superfamily growth and differentiation factor protein. |
| Protein form | Specify mature GDF-11 versus precursor, sequence boundaries, expression host, monomer or disulfide-linked dimer state, and formulation. |
| Listed presentations | 0.005, 0.01, 0.02, 0.05, 0.1 and 1 / Injectable. The dosage unit and protein construct are not stated. |
| Identity and aggregation | Request a batch identity result plus methods that distinguish intact protein, fragments, aggregates and oligomeric state. |
| Purity and bioactivity | For the allocated batch, review orthogonal purity methods, protein content and a relevant receptor-signaling or cell-based activity assay; one HPLC percentage alone is incomplete. |
| Model controls | Document endotoxin, formulation and assay controls, including possible GDF-8 or myostatin cross-reactivity in the detection system. |
Wholesale from $10.20
Published wholesale tiers apply when the order reaches 100+ total units; the tier is selected by quantity of each SKU. Smaller total orders are quoted separately.
| SKU / form | 10–24 units of this SKU | 25–49 units of this SKU | 50+ units of this SKU |
|---|---|---|---|
| 0.005 / Injectable | $13.60 | $11.90 | $10.20 |
| 0.01 / Injectable | $20.40 | $17.85 | $15.30 |
| 0.02 / Injectable | $34.00 | $29.75 | $25.50 |
| 0.05 / Injectable | $54.40 | $47.60 | $40.80 |
| 0.1 / Injectable | $81.60 | $71.40 | $61.20 |
| 1 / Injectable | $340.00 | $297.50 | $255.00 |
GDF-11 should be purchased as a defined recombinant protein reagent, not as a generic peptide powder. Sequence boundaries, host, oligomeric state and bioactivity determine whether two materials are comparable.
Confirm mature versus precursor form, sequence boundaries, expression host, purification tags, monomer or disulfide-linked dimer state and formulation.
Request intact-mass or equivalent identity evidence, orthogonal purity and aggregation methods, protein-content data and a relevant bioactivity assay for the allocated lot.
Set controls for GDF-8 or myostatin cross-reactivity and document endotoxin, residual host-cell proteins, formulation components and handling limits appropriate to the model.
The four cited papers do not point in one direction. They report different mouse systems, reagents and assays, so no rejuvenation claim or supplier-batch performance can be inferred from the literature alone.
Loffredo et al. (2013). Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy. Cell. DOI: 10.1016/j.cell.2013.04.015
Study scope: Aged-mouse cardiac-hypertrophy models and the systemic-factor experiments reported in the paper. The GDF11-related experimental material and interventions defined by the study.
What it supports: Supports describing the original report linking GDF11 with reversal of age-related cardiac hypertrophy in that mouse setting.
Boundary: The result does not establish human rejuvenation, a universal GDF11 effect, or equivalence with an unspecified recombinant lot.
Katsimpardi et al. (2014). Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors. Science. DOI: 10.1126/science.1251141
Study scope: Aging-mouse brain vascular and neurogenic measures in young-systemic-factor experiments. Young systemic factors and the interventions discussed in the paper; this is not evidence that purified GDF11 alone caused every reported outcome.
What it supports: Supports the historical context for early vascular and neurogenic findings from young-systemic-factor experiments in aging mice.
Boundary: The study must not be presented as GDF11-alone proof. It does not establish a human effect and does not validate a commercial protein preparation.
Sinha et al. (2014). Restoring Systemic GDF11 Levels Reverses Age-Related Dysfunction in Mouse Skeletal Muscle. Science. DOI: 10.1126/science.1251152
Study scope: Aged mice assessed in the skeletal-muscle experiments reported in the paper. The systemic GDF11 manipulation and study material defined by the reported protocol.
What it supports: Supports stating that an early mouse study reported improved age-related skeletal-muscle outcomes after restoring systemic GDF11 levels.
Boundary: Later literature challenged the direction of the effect. This paper does not establish a human outcome or supplier-lot performance.
Egerman et al. (2015). GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration. Cell Metabolism. DOI: 10.1016/j.cmet.2015.05.010
Study scope: Mouse and muscle-regeneration experimental systems used to reassess age-related GDF11 levels and effects. The GDF11 reagents, assays and concentrations defined by the study.
What it supports: Supports presenting the literature as conflicting rather than describing GDF11 as an established rejuvenation factor.
Boundary: Its findings are also assay- and model-dependent and do not establish a universal human effect or characterize a supplier batch.
GDF-11 is a TGF-β superfamily protein. A research lot must specify the mature or precursor construct, sequence boundaries, expression host, oligomeric state and formulation.
Early mouse studies reported selected age-related improvements, while later work reported increasing GDF11 with age and inhibited skeletal-muscle regeneration. Different assays, reagents and models limit direct comparison.
A recombinant growth factor also needs identity, protein-content, aggregation or oligomeric-state and bioactivity evidence. Endotoxin and host-cell contaminants may matter for the planned model.
The price list contains 0.005, 0.01, 0.02, 0.05, 0.1 and 1 / Injectable entries. It does not state the dosage unit, expression host or mature-protein form.
The six GDF-11 entries are priced separately by listed presentation and SKU quantity. Published tiers apply when the order reaches 100+ total units; smaller total orders are quoted separately.
Use the shipping, storage, reconstitution and in-use instructions for the exact allocated protein formulation. This page does not publish one universal condition for every construct or concentration.